Fermentation of calcium-fortified soya milk does not appear to enhance acute calcium absorption in osteopenic post-menopausal women by Cheung, ALTF et al.
Title
Fermentation of calcium-fortified soya milk does not appear to
enhance acute calcium absorption in osteopenic post-
menopausal women
Author(s) Cheung, ALTF; Wilcox, G; Walker, KZ; Shah, NP; Strauss, B;Ashton, JF; Stojanovska, L
Citation British Journal Of Nutrition, 2011, v. 105 n. 2, p. 282-286
Issued Date 2011
URL http://hdl.handle.net/10722/160593
Rights The British Journal of Nutrition. Copyright © CambridgeUniversity Press.
British Journal of Nutrition
http://journals.cambridge.org/BJN
Additional services for British Journal of Nutrition:
Email alerts: Click here
Subscriptions: Click here
Commercial reprints: Click here
Terms of use : Click here
Fermentation of calcium­fortiﬁed soya milk does not appear to enhance 
acute calcium absorption in osteopenic post­menopausal women
Anne Lise Tang Fook Cheung, Gisela Wilcox, Karen Z. Walker, Nagendra P. Shah, Boyd Strauss, John F. Ashton and Lily 
Stojanovska
British Journal of Nutrition / Volume 105 / Issue 02 / January 2011, pp 282 ­ 286
DOI: 10.1017/S0007114510003442, Published online: 21 September 2010
Link to this article: http://journals.cambridge.org/abstract_S0007114510003442
How to cite this article:
Anne Lise Tang Fook Cheung, Gisela Wilcox, Karen Z. Walker, Nagendra P. Shah, Boyd Strauss, John F. Ashton and Lily 
Stojanovska (2011). Fermentation of calcium­fortiﬁed soya milk does not appear to enhance acute calcium absorption in 
osteopenic post­menopausal women. British Journal of Nutrition, 105, pp 282­286 doi:10.1017/S0007114510003442
Request Permissions : Click here
Downloaded from http://journals.cambridge.org/BJN, IP address: 147.8.230.103 on 12 Oct 2012
Fermentation of calcium-fortified soya milk does not appear to enhance acute
calcium absorption in osteopenic post-menopausal women
Anne Lise Tang Fook Cheung1, Gisela Wilcox1,2, Karen Z. Walker3, Nagendra P. Shah1, Boyd Strauss2,
John F. Ashton4 and Lily Stojanovska1*
1School of Biomedical and Health Sciences, Victoria University, St Albans Campus, PO Box 14428, Melbourne, VIC 8001,
Australia
2Clinical Nutrition and Metabolism Unit, Monash University Department of Medicine, Monash Medical Centre, Clayton,
VIC 3168, Australia
3Department of Nutrition and Dietetics, Monash University, Clayton, VIC 3168, Australia
4Sanitarium Development and Innovation, Cooranbong, NSW 2265, Australia
(Received 15 April 2010 – Revised 27 July 2010 – Accepted 1 August 2010 – First published online 21 September 2010)
Abstract
Ageing women may choose to drink soya milk to reduce menopausal symptoms. As fermentation enriches soya milk with isoflavone
aglycones, its beneficial qualities may improve. To reduce osteoporotic risk, however, soya milk must be Ca enriched, and it is not
known how fermentation affects Ca bioavailability. A randomised crossover pilot study was undertaken to compare the Ca absorption
of fortified soya milk with that of fermented and fortified soya milk in twelve Australian osteopenic post-menopausal women. The fortified
soya milk was inoculated with Lactobacillus acidophilus American Type Culture Collection (ATCC) 4962 and fermented for 24 h at 378C.
Ca absorption from soya milk samples was measured using a single isotope radiocalcium method. Participants had a mean age of 54·8
(SD 12·3) years, with mean BMI of 26·5 (SD 5·5) kg/m2 and subnormal to normal serum 25-hydroxyvitamin D (mean 62·5 (SD 19·1) nmol/l).
Participants consumed 185 kBq of 45Ca in 44 mg of Ca carrier. The mean fractional Ca absorption (a) from soya milk and fermented
soya milk was 0·64 (SD 0·23) and 0·71 (SD 0·29), respectively, a difference not of statistical significance (P¼0·122). Although fermentation
of soya milk may provide other health benefits, fermentation had little effect on acute Ca absorption.
Key words: Calcium: Soya milk: Fermentation: Post-menopausal women
Soya milk, as a protein-rich drink containing isoflavones,
is increasingly consumed in developed countries. Potential
benefits include relief from hot flushes, improved lipid pro-
files, protection against oxidative damage to DNA and, in
particular, maintenance of bone health(1–3). Long-term
consumption of isoflavones can have bone-sparing effects
due to attenuation of bone loss(3,4). Little is known on
whether fermentation of soya milk will also affect Ca
absorption from the small intestine.
Natural soya milk contains approximately 20mg Ca/100ml
compared with cows’ milk which contains approximately
120 mg Ca/100 ml. Commercially available soya milk is
now fortified to the same level as cows’ milk by adding
fortificants such as calcium phosphate or carbonate. Not
all Ca fortificants, however, are equivalent(5). The bioavail-
ability rather than the total content of Ca in soya milk is
thus an important issue. Ca bioavailability is improved by
the presence of high amounts of soluble Ca in food(6,7)
and by facilitating ionisation of Ca in the digestive system.
One way to potentially enhance the biological activity
and nutritional value of soya milk is through fermentation
with probiotics. The fermentation of soya milk in vitro with
b-glucosidase-producing probiotic bacterial strains allows
acetyl-glucoside and b-glucoside isoflavones to undergo
enzymatic hydrolysis into biologically available aglycone
structures and also increases Ca solubility(8). Aglycones
are absorbed faster and in greater amounts than their
corresponding glucosides(9,10).
In addition, probiotics are a living microbial food sup-
plement which may have beneficial effects on symptoms
of lactose intolerance, atopic disorders and coeliac disease,
and they are useful in the treatment of diarrhoea, ulcerative
colitis and irritable bowel syndrome(11). Claims are also
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made for cholesterol-lowering effects, anti-carcinogenic
actions and improved immune function(12).
Our hypothesis is that fermented soya milk may have
greater Ca bioavailability as measured by fractional Ca
absorption than an otherwise equivalent non-fermented
soya milk.
Post-menopausal women are at high risk of osteoporosis
following increased bone loss. In the present study, we
have investigated whether fermentation of fortified soya
milk improves hourly fractional Ca absorption. A well-
established crossover radioisotope method was used
to compare Ca absorption from Ca-fortified soya milk
v. fermented Ca-fortified soya milk in osteopenic but
otherwise healthy Australian post-menopausal women.
Experimental methods
Calcium fortification of soya milk
The Ca-fortified soya milk (CFSM) used in the present
study is widely sold throughout Australia (So Good; Sani-
tarium Health Foods, NSW, Australia). It is made from
soya protein isolate (4 %) and has been fortified with a
‘proprietary’ phosphate of Ca to achieve Ca content similar
to that of cows’ milk (120 mg/100 ml).
Labelling of the fortificant with 45Ca after soya milk
manufacture
The fortificant present in the CFSM was labelled by adding
1mg of high-specific activity 45CaCl2 to a 20 ml amount of
soya milk, yielding a tracer concentration of approximately
185 kBq. Labelled CFSM was vortexed continuously for
1 min and then heat-treated (908C for 30 min) before stor-
ing at 48C for 24 h to allow for Ca exchange. The labelled
CFSM was then either given after the 24 h exchange
as the test drink or fermented before consumption
with Lactobacillus acidophilus American Type Culture
Collection (ATCC) 4962.
Bacteria
A pure culture of L. acidophilus ATCC 4962 was obtained
from the Victoria University Culture Collection (Werribee,
VIC, Australia). Purity was checked by Gram staining
before storage at 2808C in 40 % glycerol.
Fermentation of calcium-fortified soya milk
The probiotic culture L. acidophilus ATCC 4962 was acti-
vated through three successive transfers in de Man Rogosa
Sharpe broth(13) at 378C for 20 h using a 2 % inoculum. The
labelled CFSM was aseptically inoculated with a 1 % (v/v)
inoculum, incubated at 378C for 24 h and stored for a maxi-
mum period of 48 h at 48C before consumption.
Human study protocol
Twelve osteopenic but otherwise healthy post-menopausal
women aged 50–68 years were recruited by advertisement
and screened by telephone interview. Women were
included if they were post-menopausal non-smokers diag-
nosed as osteopenic (i.e. with bone mineral density T-score
21 to 22·5 as measured by dual-energy X-ray absorptio-
metry); were otherwise healthy (no chronic disease by
self-report; including gastrointestinal, kidney, liver, para-
thyroid or CVD); were not taking medications or antibiotics
affecting Ca absorption; and had not taken hormone repla-
cement therapy during the preceding 12 months. The
participants were required to be lactose tolerant and not
allergic to soya. Each completed an eating habit question-
naire (extracted from a FFQ; Australian Cancer Council,
VIC, Australia) to assess dietary Ca intake. They were
asked to avoid any Ca supplements for at least 4 weeks
before and during the study. The present study was con-
ducted according to the guidelines of the 1995 Declaration
of Helsinki as revised in Edinburgh, 2000, and all pro-
cedures were approved by the Southern Health Human
Research and Ethics Committee (project number 07013A).
Written informed consent was obtained from all the
participants.
Test milk drinks for the acute pilot study
Soya milk for the acute study had a tracer concentration of
185 kBq/dose. Each dose comprises 20 ml of the test drink
containing a microgram amount of 45CaCl2 (Amersham
Biosciences, Rydalmere, NSW, Australia) in a total 44 mg
of Ca carrier (20 mg as 45Ca and 24 mg as 40Ca present in
the CFSM). Immediately after ingestion of the test soya
milk, 200 ml of distilled water was consumed.
Study design
The participants arrived at Monash Medical Centre after an
overnight fast and were tested for Ca absorption on two
separate occasions. Treatments were randomised and given
in a crossover design study with a minimum washout
between tests of 3 weeks. At each test, the subjects
consumed either radiolabelled CFSM or radiolabelled and
fermented CFSM. At each visit, bioelectrical impedance was
determined (SFB7; Impedimed, Brisbane, QLD, Australia).
A 10 ml venous blood sample was collected from an ante-
cubital vein for a baseline sample and for measurement of
serum 25-hydroxyvitamin D. Participants then consumed
the 20 ml test drink immediately followed by the consump-
tion of 200 ml distilled water. Blood samples were collected
after 60 min as described by Nordin et al.(14). These were
centrifuged at 3500 g for 10 min, and the activity of 45Ca
in 1 ml plasma aliquots was measured using a liquid scintil-
lation counter (Wallac 1410; Perkin Elmer Life Sciences,
MA, USA). Fractional Ca (a) was then calculated(15).
Calcium absorption from fermented soya milk 283
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Calculation and statistical analysis
The sample of twelve women recruited into this crossover
design pilot study provides a probability of 90 % that
a treatment difference can be detected at the 5 % level of
significance (two sided), if the true difference between
the treatments is 15 %. This calculation is based on the
assumption that the within-patient SD of the response vari-
able is 10 %. Data from the present study were compared
by Student’s paired t test. SPSS for Windows (version
11.5; SPSS Australasia Limited, Melbourne, VIC, Australia)
was used for statistical analyses. A P value of,0·05 was
considered as significant.
Results
Comparison of calcium absorption from calcium-fortified
soya milk v. fermented calcium-fortified soya milk
Women in the study had a mean age of 54·8 (SD 12·3) years
and were overweight (mean BMI 26·5 (SD 5·5) kg/m2).
Mean serum 25-hydroxyvitamin D was 62·6 (SD 19·1) nmol/l
(range 31–96 nmol/l). Most women had normal levels,
but 38·5 % women had vitamin D insufficiency (serum
25-hydroxyvitamin D , 50 nmol/l).
The mean fractional Ca absorption (a) values for
fermented CFSM compared to CFSM were 0·71 (SD 0·29)
and 0·64 (SD 0·23), respectively. The mean fractional Ca
absorption (a) of the fermented CFSM was approximately
10 % higher compared with that of CFSM, a difference
not of statistical significance (P¼0·122). The individual
differences in fractional Ca absorption between fortified
soya milk and fermented fortified soya milk in the partici-
pants are shown in Fig. 1.
Discussion
In vitro studies indicate that fermentation of soya milk with
some probiotics may enhance Ca solubility and bioavail-
ability(8,16). To date, no other studies have examined the
effects of fermenting CFSM on Ca absorption in human
subjects. In the present study, the participants were not
vegetarian, and most of them (77 %) rarely consumed
soya milk or soya products. Around one-third (38·5 %)
of them regularly had Ca and vitamin D supplements.
All performed only low to moderate physical activity.
Habitual intake of Ca (by self-report) was moderate,
and Ca supplementation was avoided during the study.
Ca intake by the participants is, thus, unlikely to have
affected the present results; moreover, from the crossover
design of the study, each participant acted as their
own control.
The study was based on the single isotope radiocalcium
absorption test, a robust, well-validated measure of Ca
absorption(14). This method would be applicable to other
drinks fortified with Ca. The test can be completed over
a short-time period, allowing absorption from a segment
of small intestine to be followed via a sharp peak of radio-
activity(17). The rate of Ca absorption measured by this
method correlates strongly with that measured in balance
studies and correlates very highly with double isotope
Ca absorption tests(18). It is important, however, when
employing this method, to use a small Ca load (e.g. 44 mg
as here). Higher loads increase absorption time and will
reduce test sensitivity. The larger the carrier dose, the
more interference during the Ca absorption diffusion
process and the less valid the single-isotope procedure(14).
The labelling of the fortificant with 45Ca after soya milk
manufacture was shown to have a tracer distribution
pattern very similar to that when the fortificant was
labelled before the soya milk manufacture, provided a
heat treatment was applied(19). In the present study, the
soya milk fortificant was also labelled before the fermenta-
tion. No studies have indicated negative effects of probio-
tics on the availability of the 45Ca radioisotope during
Ca absorption, although a recent study found that
Ca2þ plays a positive catalytic role for human gut colonic
bacteria(20).
We have shown that fermenting CFSM with L. acidophi-
lus ATCC 4962 did not improve fractional Ca absorption
in twelve osteopenic post-menopausal women. The insig-
nificant effect of fermentation on Ca bioavailability
observed may in part reflect our choice of CFSM for
fermentation. We have previously demonstrated that the
fractional Ca absorption (a) from the CFSM used in the
present study is comparable to that of cows’ milk(19).
The fortificant present in this CFSM may already be in
its most absorbable form so that fermentation in this
case does not significantly improve acute Ca absorption.
Optimum Ca absorption (a) was observed 1 h after inges-
tion of the unfermented soya milk. It remains possible
that fermentation will improve Ca absorption in other
soya milk drinks where other methods of Ca fortification
have been used. It would thus be valuable to repeat the
present study with other types of commercially available
fortified soya milk.
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Fig. 1. Fractional Ca absorption from calcium-fortified soya milk (A) and
fermented Ca-fortified soya milk (B) in twelve individual osteopenic post-
menopausal women.
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Even without change in Ca bioavailability, fermentation
may have health benefits as it significantly increases
aglycone content (increasing daidzein, glycitein and
genistein)(8). Fermentation also increases the solubility of
Ca by decreasing soya milk pH. Moreover, the phytase
enzyme produced by some probiotics will hydrolyse
phytic acid and IP6-generating myo-inositols with reduced
numbers of phosphate groups (IP3–IP5)(21,22) causing a
beneficial effect on Ca bioavailability. In the present
study, the CFSM was made from soya protein isolate
rather than from a whole soya bean, and even before
fermentation, it had minimal phytic acid content.
Fig. 1 shows the individual fractional Ca absorption
from CFSM to fermented CFSM. Four of the twelve post-
menopausal women absorbed Ca from the fermented
CFSM better than from the non-fermented CFSM (32, 28,
69 and 31 %, respectively). These women may have
come from the approximate one-third of the population
who are ‘equol producers’, a mechanism known to facili-
tate Ca absorption(23). In further studies, it would be
advised to assess equol-producing status via 24 h urine
excretion(23). Although our acute study indicates that
fermentation of CFSM has no effect on Ca bioavailability
under conditions of acute absorption from the small
intestine, it cannot rule out the possibility that fermented
CFSM facil1itates slower Ca absorption from the large
intestine. Post hoc analysis suggests that for adequate
statistical power, 174 subjects would be needed for the
present study per treatment group. Our pilot study may
thus have been underpowered to detect any small differ-
ence in bioavailability between the two test drinks. It
does not exclude a greater difference with fermentation
in different soya milk drinks fortified by other methods.
Our findings do not therefore preclude possible benefits
on long-term consumption of fermented CFSM on bone
health and Ca balance.
In summary, during this acute pilot study, there was no
significant improvement on fractional Ca absorption from
the ingestion of CFSM fermented with L. acidophilus
ATCC 4962 in osteopenic post-menopausal women. Limi-
tations of this randomised crossover pilot study include
the sample size of twelve, the use of a test soya milk
with relatively high Ca bioavailability in its non-fermented
state and the comparison of small-intestinal Ca absorption
in the acute setting only, therefore looking at neither
differences in colonic Ca absorption nor longer-term Ca
accretion with the two test soya milk drinks. To observe
a significant improvement in fractional Ca absorption
with this particular brand of soya milk, a much larger
sample size study would be required. The effects of
fermentation might be observed more readily with soya
milk of different composition (e.g. whole bean rather
than soya protein isolate based) and Ca fortification
system. Fermentation of CFSM may also contribute to
the potential cumulative long-term benefits on Ca bio-
availability and bone health. A longer-term study, over
at least 6–12 months, looking at markers of bone turnover
and bone mineral densitometry, may be needed to test
this hypothesis further.
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